In groundbreaking research from the University at Albany, a sophisticated technique leveraging Raman spectroscopy has been developed to ascertain whether mRNA is fully and correctly enclosed within lipid nanoparticles. Unlike conventional methods that necessitate the disruptive breakdown of nanoparticle structures, this approach offers a non-destructive, rapid assessment of mRNA encapsulation directly in the intact formulation. Raman spectroscopy, a laser-based analytical tool, probes molecular vibrations by measuring scattered light, yielding a chemical fingerprint unique to each material. By illuminating the sample with a laser and analyzing the spectrum of scattered photons, scientists can decode the molecular composition and interactions without physically altering the sample.

This innovative methodology hinges on the use of deep ultraviolet (UV) resonance Raman spectroscopy, a specialized variant designed to enhance the signal from nucleic acids in the presence of lipids. Since mRNA constitutes only a minor fraction within the lipid-rich environment of nanoparticles, its spectral signature is easily masked by the surrounding lipids when using traditional Raman spectroscopy. Deep UV excitation, however, exploits the intrinsic absorbance properties of nucleic acids, amplifying their Raman response while suppressing interference from lipids. This allows for selective observation of mRNA molecules nestled inside the nanoparticles, thus providing an unparalleled window into the quality of encapsulation.

Led by Professor Igor Lednev, the research team crafted a bespoke deep-UV Raman instrument capable of precisely targeting mRNA molecules in complex vaccine samples. The instrument generates laser light at ultraviolet wavelengths, harnessing resonance effects to magnify the otherwise weak spectral signals from RNA. Coupled with advanced statistical models and machine learning algorithms, the system quantitatively evaluates whether each mRNA strand is fully sequestered within lipid vesicles or partially exposed, which could undermine therapeutic efficacy. This analytical innovation not only preserves the sample intact for further testing but also promises to dramatically accelerate quality control processes in vaccine and therapeutic development.

The implications of this technology are profound, particularly as mRNA vaccines become a mainstay in global healthcare. Current analytical techniques to verify lipid nanoparticle integrity often involve destructive sample preparation, including chemical disruption or extraction procedures that obliterate the native structure. These methods are laborious and incapable of providing rapid feedback during manufacturing or research. By contrast, Raman spectroscopy offers instantaneous chemical characterization, maintaining the original state of the vaccine formulation. Such real-time monitoring capabilities could enable pharmaceutical manufacturers to optimize lipid formulations iteratively, balancing the requirements of stability, delivery efficiency, and safety.

Professor Alexander Shekhtman, a collaborator on the project and an expert in RNA biochemistry at the University at Albany’s RNA Institute, underscores the method’s ability to surmount longstanding hurdles in nanoparticle analysis. “The fragility of intact lipid nanoparticles and their heterogeneity have historically complicated characterization efforts,” Shekhtman explains. “Our application of Raman spectroscopy allows the analysis of mRNA within these particles without compromising their structure, facilitating the design of next-generation therapeutics with improved profiles.” This approach may herald a paradigm shift in how researchers and manufacturers evaluate mRNA delivery systems.

Beyond its immediate application to mRNA encapsulation, the technology reflects a broader trend toward integrating advanced photonic tools with computational analytics in biomedicine. Raman spectroscopy itself has endured as a versatile method in chemistry and materials science, yet its fusion with powerful data-driven interpretation—such as machine learning—enhances resolution and specificity. Professor Lednev’s lab has been at the forefront of this convergence, previously pioneering Raman-based methods for forensic investigations and the early detection of neurodegenerative diseases via noninvasive molecular fingerprints. The current advancement embodies the lab’s commitment to translating optical spectroscopy innovations into impactful biomedical solutions.

This laser-driven analytical advance could soon become indispensable not only in late-stage quality control but also in the early research phases of mRNA therapeutic design. By providing immediate feedback on nanoparticle formulation efficacy, researchers can rapidly iterate on lipid compositions and mRNA loading strategies to optimize delivery mechanisms. The ability to non-destructively verify encapsulation ensures that formulations entering clinical trials have consistent, reproducible quality, ultimately driving safer and more effective treatments for patients worldwide.

The collaboration that fueled this breakthrough spans continents, engaging researchers from the University at Albany and Kangwon National University in South Korea. Sila Jin and Young Mee Jung contributed to the project, supported by a training grant from the National Research Foundation of Korea. Their partnership highlights the increasingly globalized nature of biomedical innovation, wherein expertise and technology coalesce across borders to solve pressing healthcare challenges.

This research exemplifies how advances in laser spectroscopy and photonics can be harnessed to meet the precise demands of modern medicine. By unveiling the molecular intricacies of mRNA encapsulation within lipid nanoparticles, the technique offers a powerful tool to ensure that these cutting-edge therapeutics reach patients with the highest standards of safety and effectiveness. As mRNA therapies continue to evolve, such analytical breakthroughs will be critical pillars supporting their widespread adoption and success against a myriad of diseases.

—

Subject of Research: Analysis of mRNA encapsulation within lipid nanoparticles using deep ultraviolet Raman spectroscopy.

Article Title: Encapsulation of mRNA in Therapeutics Like Lipid Nanoparticles Probed by Deep-UV Resonance Raman Spectroscopy

News Publication Date: February 26, 2026

Web References:
https://pubs.acs.org/doi/10.1021/acs.analchem.5c04246

References:
Igor Lednev et al., Analytical Chemistry, 15-Jan-2026, DOI: 10.1021/acs.analchem.5c04246

Image Credits:
Patrick Dodson / The Lednev Lab

Keywords

Analytical chemistry, Spectroscopy, RNA, Messenger RNA, Lipid nanoparticles, mRNA therapeutics, Deep-UV Raman spectroscopy, Molecular diagnostics, Vaccine quality control

Tumors, especially of the solid variety, are notorious for their ability to create an exceptionally stiff and dense extracellular matrix, largely composed of collagen. This physical barrier not only impedes the infiltration of immune cells but also severely restricts the effective delivery of therapeutic agents. In particular, modern immunotherapies that utilize RNA encapsulated within lipid nanoparticles demand unhindered access to the tumor core to activate immune responses effectively. Overcoming this barricade has long been a critical challenge for oncologists and researchers alike.

The research team led by Efstathios “Stathis” Karathanasis and Agata Exner devised an extraordinary method by injecting nanobubbles filled with inert perfluoropropane gas directly into tumors. Once these microscopic bubbles are in place, carefully tuned ultrasound waves are applied to oscillate or “jiggle” them. This mechanical stimulation disrupts the rigid collagen network without causing cellular damage, softening the tumor microenvironment and thus rendering it more permeable. The process acts like a molecular locksmith, unlocking the tumor’s defenses to therapeutic molecules and immune cells.

Details from the study reveal that within a breast cancer model, the ultrasound-activated nanobubbles caused the tumor matrix to become softer and more uniform. This alteration was not merely superficial; it facilitated the enhanced penetration of immune cells and nanoparticles deeper into the tumor mass. The significance of this lies in the improved efficacy of immunotherapies, as these treatment molecules can reach their cellular targets more effectively, potentially translating into better clinical outcomes.

What makes this approach particularly compelling is its dual function: not only does it dismantle the tumor’s physical shields, but it also triggers an intrinsic immunological response. The treated tumors exhibited activation of resident immune cells, which began secreting danger signals that attract additional immune components. Remarkably, the killer T cells mobilized from the treated tumor extended their activity systemically, seeking out and attacking untargeted tumor sites elsewhere in the body, indicating a systemic immune boost initiated by localized treatment.

The durability of this therapeutic window is another promising aspect. The nanobubble treatment maintained softened tumor tissue for at least five days, providing an extended timeframe during which other therapies, such as RNA-based immunotherapies, could be administered with increased efficiency. This contrasts sharply with untreated tumors, which typically continue to stiffen and become even more resistant to treatment over time.

One of the most attractive features of this novel technology is its readiness for rapid clinical translation. The nanobubbles employed are already in use commercially for prostate cancer detection, and the ultrasound devices necessary for activation are FDA-approved and widely available in medical settings. This existing regulatory framework and technological infrastructure could dramatically shorten the timeline for human trials and eventual patient access.

Agata Exner, a pioneering expert in radiology and nanomedicine who directs the CWRU Center for Imaging Research, emphasized the broad applicability of this technology. Solid tumors in organs such as the liver, prostate, and ovaries—which are often challenging to treat due to their dense extracellular environment—could greatly benefit from this strategy. Given that ultrasound is a routine diagnostic modality for these tumors, integrating this therapeutic approach could be seamless and cost-effective.

The commercial potential of this technology is exemplified by Exner’s role in founding Visano Theranostics, a company aimed at bringing nanobubble applications into clinical practice. Their forthcoming Investigational New Drug submission to the FDA within the next 18 months highlights a clear roadmap to clinical trials, with hopes of therapeutic applications following swiftly. This proactive stance underscores the translational nature of their research.

Funding from the National Institutes of Health and the Case Comprehensive Cancer Center has been pivotal in supporting this research, further validating its significance in the scientific and medical community. The collaboration demonstrates a multidisciplinary convergence of nanotechnology, biomedical engineering, immunology, and clinical medicine—a testament to modern scientific innovation addressing complex medical challenges.

This breakthrough offers an exciting glimpse into the future of cancer therapy, where the physical and biological obstacles tumors erect can be methodically disassembled, enabling existing and emerging immunotherapies to perform at their full potential. By turning the tumor’s own defenses against itself, this strategy may redefine therapeutic success and improve survival rates for patients afflicted with notoriously resistant cancer types.

As the research progresses towards clinical implementation, patients and physicians alike can look forward to a novel adjunctive therapy that enhances the reach and impact of immuno-oncology treatments. The integration of nanobubbles and ultrasound could become a new frontier in oncology, offering hope where traditional treatments have reached their limits.

Subject of Research:
Nanotechnology-enabled modulation of tumor microenvironment to improve immunotherapy delivery in solid tumors.

Article Title:
Enhanced Delivery of Lipid Nanoparticle-Based Immunotherapy by Modulating the Tumor Tissue Stiffness Using Ultrasound-Activated Nanobubbles

News Publication Date:
28-Jan-2026

Web References:
https://pubs.acs.org/doi/10.1021/acsnano.5c21787
http://case.edu/

About Us

References:
Karathanasis, Efstathios S., et al. “Enhanced Delivery of Lipid Nanoparticle-Based Immunotherapy by Modulating the Tumor Tissue Stiffness Using Ultrasound-Activated Nanobubbles.” ACS Nano, 2026.

Image Credits:
Case Western Reserve University

Keywords:
Nanomedicine, Cancer immunology, Tumor microenvironments, Biomedical engineering, Cancer